Jieun Kwon et al demonstrated reduced signs and symptoms of dry eye disease (DED) in afflicted patients in response to a new eye drop treatment made from pooled human antibodies. The immunoglobulin pool targets anti-citrullinated protein autoantibodies, or ACPAs-a specific type of antibody, found in human tear fluid. ACPAs were found to be involved in eye inflammation by contributing to the development of neutrophil extracellular traps (NETs) on the surface of the eyes. Researchers had identified earlier that strands of DNA extrude from neutrophils led to the formation of these NET webs on the surface of the eyes of mice affected by severe dry eye disease and cause inflammation. They found that people using the antibody-based eyewash (IVIG 4 mg/mL) twice a day for 8 weeks showed a statistically significant and clinically meaningful reduction in corneal damage compared with the control group. In the test group, the amount of pro-inflammatory biomarkers or dry areas also was reduced on the surface of the eye. The study suggests that pooled immune globulin-eye drops could become a potential new class of biologic therapy for dry eye patients.
Source:The Ocular Surface,10 October 2019 https://doi.org/10.1016/j.jtos.2019.10.004